Lifevantage (NASDAQ:LFVN) Posts Earnings Results

Lifevantage (NASDAQ:LFVN) posted its quarterly earnings data on Wednesday. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.07), FiscalAI reports. The business had revenue of $48.93 million for the quarter, compared to analyst estimates of $54.40 million. Lifevantage had a return on equity of 33.52% and a net margin of 4.43%.

Lifevantage Price Performance

NASDAQ LFVN traded up $0.19 during trading hours on Wednesday, hitting $5.55. The company had a trading volume of 196,672 shares, compared to its average volume of 226,780. The firm’s 50 day moving average is $6.25 and its 200 day moving average is $8.99. Lifevantage has a fifty-two week low of $5.15 and a fifty-two week high of $24.05. The company has a market capitalization of $70.49 million, a price-to-earnings ratio of 7.21 and a beta of 0.33.

Wall Street Analyst Weigh In

Several research firms have commented on LFVN. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a research note on Monday, December 29th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Lifevantage in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Lifevantage has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Insider Buying and Selling at Lifevantage

In other news, Director Michael A. Beindorff sold 12,607 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $6.42, for a total value of $80,936.94. Following the completion of the sale, the director owned 43,806 shares of the company’s stock, valued at $281,234.52. This represents a 22.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 48,607 shares of company stock valued at $330,467 over the last ninety days. 21.95% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lifevantage

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in shares of Lifevantage by 870.2% in the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after purchasing an additional 4,499 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage in the 2nd quarter worth $76,000. BNP Paribas Financial Markets boosted its position in Lifevantage by 2,555.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after buying an additional 5,904 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Lifevantage during the first quarter valued at about $97,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Lifevantage during the second quarter worth about $102,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.